Lilly Expects FDA Action On Symbyax For Treatment-Resistant Depression In Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
After receiving an “approvable” letter in March for treatment-resistant depression, firm says it is working with the agency to determine labeling and post-marketing commitments.